

For Immediate Release

**MedX[®] Announces Positive Results
From Low-Level Laser Therapy Study in Wound Healing**

*Research results presented at the
World Union of Wound Healing Societies Congress 2008 in Toronto*

Mississauga, Ontario ó June 5, 2008 ó MedX Health Corp. (TSXV: MDX) today announced the publication of positive results from a study of low-level laser therapy (LLLT) for healing acute and chronic wounds combined with the Extendicare Wound Prevention and Management Program. Although the study was completed a number of years ago, these positive results are just being presented formally, and for the first time are appearing in the peer-reviewed journal, *International Wound Journal*. The nine-week study evaluated the effect of low-level laser therapy on wound healing in 16 patients at a Canadian Extendicare nursing home. At the end of the study, 61.9 percent of the wounds achieved significant improvement (> 50 percent wound closure) and 42.8 percent had 100 percent closure. None of the wounds deteriorated during the study and no negative consequences of treatment were encountered. In addition, a retrospective review of the data revealed an estimated total cost savings of \$220 per month per patient in labor and supplies.

“We are very pleased with the positive research results of our low-level laser system in wound care,” said Steve Guillen B.Sc., M.B.A., President and Director, MedX Health. “Pressure ulcers and chronic wounds are a common and costly problem in nursing home settings. MedX has a long history of offering innovative laser and light therapy products that have successfully treated pain, sports injuries and other conditions and we believe our products can offer patients with acute and chronic wounds a non-invasive, drug free solution.”

Chronic wounds can be painful and debilitating for patients and the care and management of these wounds can have significant economic consequences. The study results demonstrate that MedX’s low-level laser system was very easy to learn and use and offered relief for frail and elderly patients who suffered from acute and chronic wounds.

The study results indicated similar wound closure rates were achieved for both chronic and acute wounds, suggesting LLLT may play an important role in enhancing wound healing regardless of chronicity. In addition, previous research has demonstrated LLLT increases microcirculation and tensile strength of new tissue, offering a potential opportunity for LLLT in the preventative treatment of recently closed wounds that have a history of reopening. Additionally, MedX LLLT provided sufficient pain control from a lack of blood flow to the area, to allow a couple of patients in chronic pain to sleep and participate more in their daily activities. Finally, an anecdotal result of the study showed increased vigilance and active participation by the health care workers at the facility who participated in the research due to having a concrete treatment option for these difficult-to-manage wounds.

About Low-Level Laser Therapy

For more than 35 years, LLLT has been used in Europe, Australia, Asia and Russia for the treatment of pain and tissue repair. LLLT was approved in Canada in the early 1990s and in the United States in 2002. LLLT uses a specific type of light to penetrate the skin's surface and underlying tissues to stimulate the body's natural repair processes. The result is faster healing and reduced pain, swelling and inflammation.

The MedX 1000 Console system used in the study has two 80 mW infrared laser clusters for large area treatment and one 50 mW single diode infrared laser probe for more focused, deeper applications. The study incorporated LLLT into the established, standardized Extencare Wound Prevention and Management Program.

About MedX Health Corp.

MedX is a leading North American developer and manufacturer of phototherapy medical devices, including dental, rehabilitation and wound care products. MedX plans to use the proceeds from its recent public offering to expand its distribution network; support its marketing program; continue development of new dental, rehabilitation and wound care products; undertake research and development for wound care products; and for working capital purposes. In particular, MedX plans to accelerate the development of a new product aimed at the rapidly-growing wound care market: its *Photobandage*, a bandage technology that allows a wound to be bathed in light, designed to enhance the healing process. The Company intends to license this new technology to one or more major wound care companies for further development, marketing and sales.

For further information, please contact:

Steve Guillen
President & Director, MedX Health Corp.
Phone: (905) 826-0766
Email: guillen@medxhealth.com

Nelson Smith
Taddle Creek Capital
Phone: (416) 565-7518
Email: smith@medxhealth.com

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this press release.

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Such forward-looking information may include statements regarding the Company's future plans, objectives, performance, growth, profits, operating expenses or its underlying assumptions. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects", or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "does not anticipate", or "believes" or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", or "will be

taken", "occur", or "be achieved". Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of MedX to be materially different from those expressed or implied by such forward-looking information, including uncertainty of successful development of new products, uncertainty of successful manufacturing or marketing of products, uncertainty of commercial acceptance of products, uncertainty concerning governmental regulation, dependency on key employees and relationships, rapid technological changes, foreign currency fluctuations. MedX does not undertake to update any forward-looking information, except in accordance with applicable securities laws.